23:35 , Nov 20, 2018 |  BC Extra  |  Company News

Merck KGaA, Palantir team up to drive cancer research data sharing and integration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
00:53 , Nov 20, 2018 |  BC Extra  |  Clinical News

Bavencio fails Phase III for ovarian cancer

Hopes for Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) to get ahead in the ovarian cancer space, where no PD-1/PD-L1 inhibitors are approved, were delayed Monday after the partners reported that PD-L1 inhibitor Bavencio avelumab...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures on Nov. 13. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did...
11:35 , Nov 13, 2018 |  BC Extra  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did existing investors SV...
11:33 , Nov 13, 2018 |  BioCentury  |  Finance

Playing in RNA

M Ventures, the strategic venture arm of Merck KGaA (Xetra:MRK), is adding another RNA company to its portfolio by leading a $30 million series A round for Ribometrix Inc. Fellow new investors Amgen Ventures, Pappas...
00:11 , Nov 10, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
18:25 , Nov 9, 2018 |  BC Week In Review  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
13:33 , Nov 6, 2018 |  BC Extra  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
00:34 , Nov 3, 2018 |  BioCentury  |  Finance

Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs...
20:48 , Oct 23, 2018 |  BC Extra  |  Company News

Management tracks: Celgene, Seres, AC Immune

Celgene Corp. (NASDAQ:CELG) hired Alise Reicin as president of global clinical development, a newly created position. She was SVP and head of global clinical development in R&D at the EMD Serono business of Merck KGaA...